Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Vildagliptin Quiz

Total questions: 20

Worksheet time: 10mins

Name
Class
Date
1.

Vildagliptin was first synthesized by researchers at which company?

a)

USV

b)

Novartis

c)

Torrent

d)

Alkem

2.

USV launched Jalra in partnership with which multinational company?

a)

Sanofi

b)

Novartis

c)

GSK

d)

Cipla

3.

Jalra OD contains which form of Vildagliptin?

a)

Immediate release 100 mg

b)

Sustained release 100 mg

c)

Controlled release 50 mg

d)

Delayed release 100 mg

4.

Recommended daily dose of Vildagliptin is:

a)

50 mg OD

b)

50 mg BID

c)

100 mg OD

d)

150 mg OD

5.

As per VA, Jalra OD should be added on to which therapy?

a)

Metformin alone

b)

SU or SU + Metformin

c)

Insulin only

d)

DPP4 inhibitor

6.

Jalra M is preferred for:

a)

Drug naïve T2DM patients

b)

Uncontrolled on Metformin

c)

Patients with CV risk

d)

Pediatric diabetes

7.

Jalra DP is indicated for T2DM patients with:

a)

High HbA1c

b)

CV risk

c)

Renal impairment

d)

Weight gain

8.

The result of DPP-4 inhibition by Vildagliptin is:

a)

Reduced insulin secretion

b)

Enhanced incretin activity

c)

Increased glucagon

d)

Reduced GLP-1

9.

Vildagliptin provides how many extra hours in range compared to Sitagliptin?

a)

1 hour

b)

2 hours

c)

3 hours

d)

4 hours

10.

The VERIFY trial demonstrated:

a)

Higher hypoglycemia with Vilda+Met

b)

Reduced second treatment failure

c)

Weight gain

d)

No difference in HbA1c

11.

Early combination of Vildagliptin + Metformin improved which function?

a)

Renal

b)

Liver

c)

Beta cell

d)

Alpha cell

12.

Which of the following is NOT a benefit of Vildagliptin?

a)

Weight neutrality

b)

Reduction in glycemic variability

c)

Risk of edema

d)

Improvement in insulin sensitivity

13.

Vildagliptin is safe for use in:

a)

Pediatric

b)

Liver impaired

c)

Mild-to-severe renal impairment

d)

Pregnant women

14.

Which patient group requires no dose adjustment with Vildagliptin?

a)

Geriatric

b)

Hepatic

c)

Pediatric

d)

Pregnant

15.

Vildagliptin shows how much HbA1c reduction?

a)

0.48%

b)

0.71%

c)

1.1%

d)

0.9%

16.

Vildagliptin has what kind of cardiovascular profile?

a)

Harmful

b)

Neutral/Safe

c)

High-risk

d)

Unknown

17.

For eGFR <30 ml/min, the dose of Vildagliptin is:

a)

25 mg

b)

50 mg

c)

75 mg

d)

Not recommended

18.

How does Vildagliptin differ from Sitagliptin in excretion profile?

a)

Completely hepatic

b)

Predominantly renal

c)

Intermediate renal excretion

d)

Non-renal

19.

Jalra OD provides bioequivalence to:

a)

Vildagliptin 50 mg OD

b)

Vildagliptin 50 mg BID

c)

Vildagliptin 100 mg BID

d)

Vildagliptin 50 mg TID

20.

Jalra OD is suitable for:

a)

Pediatric diabetes

b)

Patients on insulin or dual/triple therapy

c)

GDM patients

d)

Newly diagnosed only